Volume 6.22 | Jun 12

Cord Blood News 6.22 June 12, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Umbilical Cord Blood Expansion with Nicotinamide Provides Long-Term Multilineage Engraftment
Researchers tested the hypothesis that an umbilical cord blood-derived cell product consisting of stem cells expanded for 21 days in the presence of nicotinamide and a noncultured T cell fraction can accelerate hematopoietic recovery and provide long-term engraftment. [J Clin Invest] Full Article | Press Release
Learn more: StemSpan™ Megakaryocyte Expansion Supplement
PUBLICATIONS (Ranked by impact factor of the journal)
IGF2BP1 Expression in Human Mesenchymal Stem Cells Significantly Affects Their Proliferation and Is Under the Epigenetic Control of TET1/2 Demethylases
Scientists demonstrated that mesenchymal stem cells of adipose tissue, bone marrow, and umbilical cord blood origin have a differential pattern of IGF2BP1 and TET1/2 expression that could correlate with their proliferation potential. [Stem Cells Dev] Abstract

Hypoxia/Hypercapnia-Induced Adaptation Maintains Functional Capacity of Cord Blood Stem and Progenitor Cells at 4°C
The authors analyzed the effect of exposure to hypoxic/hypercapnic gas mixture (5% O2/9% CO2) on the maintenance of functional cord blood CD34+ hematopoietic stem and progenitor cells in severe hypothermia (4°C) employing the physiological and proteomic approaches. [J Cell Physiol] Abstract

Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts
Investigators studied 459 consecutive patients with hematologic malignancies, with a median age of 44 years, grafted from identical siblings, matched unrelated donors, mismatched unrelated donors, unrelated cord blood or HLA haploidentical family donors. [Biol Blood Marrow Transplant] Abstract

Human Umbilical Cord-Derived Mesenchymal Stem Cells Do Not Undergo Malignant Transformation during Long-Term Culturing in Serum-Free Medium
Data showed that human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) met the International Society for Cellular Therapy standards for conditions of long-term in vitro culturing at P15. Since hUC-MSCs can be safely expanded in vitro and are not susceptible to malignant transformation in serum-free medium, these cells are suitable for cell therapy. [PLoS One] Full Article

Long-Term MRI Cell Tracking after Intraventricular Delivery in a Patient with Global Cerebral Ischemia and Prospects for Magnetic Navigation of Stem Cells within the CSF
After approval by the Institutional Review Board, an 18-month-old patient, diagnosed as being in a vegetative state due to global cerebral ischemia, underwent cell transplantation to the frontal horn of the lateral ventricle, with umbilical cord blood-derived stem cells labeled with superparamagnetic iron oxide contrast agent. [PLoS One] Full Article

Clinical Outcomes of AML Patients Relapsing after Matched-Related Donor and Umbilical Cord Blood Transplantation
AML relapse remains the leading cause of transplant failure among Allo-SCT recipients. A single institution study was conducted on 348 patients with AML who received an Allo-SCT from an umbilical cord blood or HLA-matched-related donor. [Bone Marrow Transplant] Abstract

Improving Cord Blood Unit Quantity and Quality at King Abdullah International Medical Research Center Cord Blood Bank
The authors established a public cord blood bank at a tertiary hospital in Saudi Arabia. They investigated the reasons behind rejecting or not collecting cord blood units over two years and which steps were implemented to improve the number and quality of storable units. [Transfusion] Abstract

Generation of a Biomimetic Human Artificial Cornea Model Using Wharton’s Jelly Mesenchymal Stem Cells
Scientists have demonstrated for the first time the capability of Human Wharton’s jelly stem cells to differentiate in vitro into cornea epithelial-like cells using a three dimensional model based on fibrin-agarose human bioengineered corneas. [Invest Ophthalmol Vis Sci] Abstract

Heading to ISSCR 2014 in Vancouver?
Come Visit Connexon Creative at Booth #507 and Enter to Win $100 Amazon Gift Card!

Learn how to complete, submit and review BMT registry forms locally. Join the Webinar.
Hematopoietic Stem Cell Transplantation Donor Sources in the 21st Century: Choosing the Ideal Donor When a Perfect Match Doesn’t Exist
Most patients who require allogeneic stem cell transplantation do not have a matched sibling donor, and many patients do not have a matched unrelated donor. In an effort to increase the applicability of transplantation, alternative donors such as mismatched adult unrelated donors, haploidentical related donors, and umbilical cord blood stem cell products are frequently used when a well matched donor is unavailable. [Blood] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Accelerate Your Cell Therapy to Market - Cell Therapy Bioprocessing 2014
Americord Joins Governor Cuomo’s Start-Up NY Initiative
Americord announced that it will expand its presence in New York as a result of START-UP NY, an initiative that creates tax-free areas across New York State. Under the program, Americord will invest more than $402,000 toward a new research and development laboratory and spur the creation of new jobs. [Americord Registry] Press Release

Conrad T. Prebys Gives $25 Million to Salk Institute to Support Scientific Research
The Salk Institute for Biological Studies has received a $25 million gift from San Diego philanthropist and former Salk trustee Conrad T. Prebys to support cutting-edge biological research on a wide range of diseases. [The Salk Institute for Biological Studies] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW South Central Association of Blood Banks & Association of Donor Recruitment Professionals Joint Educational Symposium
July 18, 2014
Fort Worth, United States

NEW World Alliance Forum in San Francisco – The Impact of Regenerative Medicine 2014
November 6-7, 2014
San Francisco, United States

NEW The World Stem Cell Summit 2014
December 3-5, 2014
San Antonio, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

NEW Postdoctoral Researcher – Novel PSC-Based Blood Therapeutics (Fred Hutchinson Cancer Research Center)

Research Associate – Hematology/Oncology (University of Chicago)

Postdoctoral Researcher – Hematopoietic Stem Cells & iPSCs (KU Leuven)

Postdoctoral Fellow – Cell Therapy with Umbilical Mesenchymal Stem Cells (University of Cincinnati)

Postdoctoral Research Scientist – Immunotherapy (The Anthony Nolan Trust)

Postdoctoral Fellowship – Hematology, Immunology, Cancer Therapeutics (The Research Institute, Nationwide Children’s Hospital)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us